The firm is lowering its guidance due to anticipated revenue loss related to remediation efforts associated with its Alaris pump system.
The deal with Quaphaco includes minimum Unyvero A50 instrument and infectious disease test cartridge purchases of €1.9 million over the initial three-year term.
Contributing to the Japanese diagnostic firm's higher revenues were increased instrument and reagent sales both domestically and internationally.
The company said the funding will support international expansion of its FebriDx rapid point-of-care test and its US clinical trial.
Qiagen's Q4 revenues of $413.5 million represented 4 percent growth at constant exchange rates and bested Wall Street's expectation of $405.6 million.
The firm said that in fiscal Q2, its China businesses continued to achieve greater than 20 percent growth, but its European business growth was soft year over year.
The funding will support up to 90 percent of development costs for the Klaris system, which purportedly performs phenotypic testing in four hours.
Of the 28 companies in the index, 16 companies' share prices increased while the share values of 12 declined month over month.
The company announced Monday that it has inked a contract to become the primary supplier of products for immunoassay testing to Quest Diagnostics.
The partners aim to develop new diagnostic technologies and businesses, with a focus on diseases for which there are no established diagnostic methods.
China remains a key strategic market for Roche, and it said that it has multiple assays for 2019-nCoV coronavirus for research-use only.
The Chinese company has also granted the underwriters of the offering an option to purchase an additional 200,004 ADS to cover overallotments.
Revenues for the quarter were $1.93 billion, with the company attributing the growth to expanded access to insurer networks and good operational execution.
A subsidiary of Curetis, a firm recently merged with OpGen, Ares will use BGI technology to sequence samples in Europe.
While overall revenues and net income were up, analytical instruments revenues decreased 3 percent in Q4, and 2 percent organically.
Roche's overall revenues increased 9 percent, with an 11 percent increase in pharmaceuticals along with the rise in diagnostics revenues.
The company also reported higher expenses, in part due to R&D around its MosaiQ platform for blood grouping and transfusion-transmitted infection screening.
Life Sciences revenues grew 7 percent year over year to $1.92 billion, while Diagnostics revenues were up rose also 7 percent to $1.80 billion.
Within diagnostics, the firm posted molecular diagnostics revenues of $178.5 million, up 9 percent from $164.3 million in fiscal Q1 2019.
Uppsala University spinout Astrego has developed a system to rapidly detect bacterial infection and antibiotic susceptibility in biofluid.